ARTICLE | Company News
Roche (SIX:ROG; OTCQX:RHHBY) will pay Ionis Pharmaceuticals Inc. (NASDAQ:IONS) $75 million up front for an option to develop and commercialize IONIS-FB-LRx, a ligand-conjugated antisense (LICA) oligonucleotide targeting complement factor B (CFB).
The partners plan to develop the candidate for complement-mediated diseases, with an initial focus on geographic atrophy, the advanced stage of dry age-related macular degeneration (AMD)...